Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Lipidology

Long-Term Monitoring, Risks, and Family Planning

At a Glance

Familial chylomicronemia syndrome requires lifelong monitoring because high triglycerides can repeatedly injure the pancreas and affect digestion, blood sugar, and liver health. Specialist care before pregnancy and genetic counseling can support safer family planning.

Familial Chylomicronemia Syndrome (FCS) is a lifelong condition. Because your body will always have difficulty clearing fat, your health plan must focus on protecting your organs from the cumulative effects of high triglycerides over many decades. With proper monitoring and a dedicated care team, it is possible to manage these risks and plan for a healthy future [1][2].

Protecting the Pancreas for the Long Term

The primary goal of long-term care is to prevent acute pancreatitis (sudden inflammation). However, even small, repeated injuries to the pancreas can lead to permanent changes over time.

  • Chronic Pancreatitis: This is permanent scarring of the pancreas. It can lead to long-term abdominal pain that is difficult to manage [3].
  • Exocrine Pancreatic Insufficiency (EPI): If the pancreas becomes too scarred, it can no longer produce the enzymes needed to digest food. This can cause weight loss, bloating, and oily or pale stools [3][4].
  • Type 3c Diabetes: When the parts of the pancreas that produce insulin are damaged by repeated injury, you can develop a specific type of diabetes. One cohort found that people with FCS were much more likely to develop diabetes than those without the condition [5][6].
  • Liver Health: High fat in the blood can also affect the liver. In some cohorts, 42% of people with FCS were observed to have hepatic steatosis (fatty liver), which can occur even if you have a low body weight [7].

Note: These are potential complications of recurrent pancreatic injury, not inevitable guarantees for every patient with FCS.

Your Surveillance Schedule

To catch these complications early, you will need regular check-ups. While every patient is different, a typical surveillance plan often includes:

  • Fasting Triglycerides: Checked frequently. While diagnostic levels are often cited above 885–1,000 mg/dL, pancreatitis risk rises above approximately 500 mg/dL. A value below 1,000 mg/dL can still carry severe risk. Your specialist will set a highly individualized target for you [8][9]. If you have severe abdominal pain, seek emergency care regardless of your last recorded triglyceride number.
  • Blood Sugar (HbA1c): Checked at least annually to screen for early signs of diabetes [4].
  • Nutritional Labs: Regular checks of fat-soluble vitamins (A, D, E, K) and essential fatty acids to ensure your strict diet isn’t causing deficiencies [1][10].
  • Specialty Monitoring: If you take targeted therapies like volanesorsen, you will need frequent blood tests to strictly monitor your platelets (the cells that help your blood clot) [11][12].

Pregnancy and FCS

Pregnancy is a high-risk period because hormone changes naturally cause triglyceride levels to rise significantly (often 100% to 300% during gestation), which can trigger severe pancreatitis [13]. In one retrospective cohort, 42% of women with FCS experienced at least one episode of pancreatitis during their pregnancy [14].

If you are planning to become pregnant:

  • Preconception Planning: Meet with a Maternal-Fetal Medicine (MFM) specialist and your lipidologist before conceiving. Many targeted lipid therapies have limited pregnancy safety data and must be carefully reviewed [13][15]. Do not start or stop medications independently.
  • Therapeutic Plasma Exchange (TPE): This is a procedure where your blood is filtered to physically remove the excess fat. It is not routine prophylaxis. It is sometimes used on a case-by-case basis in expert centers for extreme or refractory hypertriglyceridemia. It carries procedural risks and its benefits may be temporary [16][17].
  • Dietary Rigor: You will need a specialized dietitian to help you balance the extreme low-fat needs of FCS with the increased calorie and nutrient needs of a growing baby [1][14].

Family Planning and Cascade Screening

Because FCS is an autosomal recessive condition, it is caused by inheriting a pathogenic variant from both parents [18]. This has important implications for your family:

  • Risk to Children: If you have FCS, you will pass one pathogenic variant to each of your children, making them obligate carriers. A child is at risk for developing FCS only if your partner also passes down a pathogenic variant in the same gene [19].
  • Carrier Status: Most heterozygous carriers (people with only one variant) do not have FCS, although they might have other genetic or metabolic factors that affect their lipids [20].
  • Cascade Screening: A genetic counselor can help tailor a testing plan for your family based on specific probabilities, rather than advising broad testing without context. Children in affected families who show signs (like milky blood during routine draws) should have their lipids checked early [21][22]. Your counselor will assist you in navigating these decisions [23][24].

Common questions in this guide

How often should triglycerides and blood sugar be checked in FCS?
Fasting triglycerides are usually checked frequently, with the schedule and target set by your lipid specialist. HbA1c is often checked at least once a year, but severe abdominal pain needs emergency evaluation regardless of your last result.
What long-term complications can familial chylomicronemia syndrome cause?
Repeated pancreatic injury can lead to chronic pancreatitis, digestive enzyme deficiency, and type 3c diabetes; FCS is also associated with fatty liver. These complications are possible, not inevitable, and regular monitoring helps identify changes early.
What signs might mean my pancreas is not digesting food properly?
Weight loss, bloating, and oily or pale stools can suggest that the pancreas is not making enough digestive enzymes. Tell your healthcare team about persistent changes so they can decide whether testing or treatment is needed.
What should I do before becoming pregnant with FCS?
Meet with a lipid specialist and a maternal-fetal medicine specialist before trying to conceive. Pregnancy can raise triglycerides substantially, so your team should review medications and create a plan for diet, blood tests, and urgent care; do not start or stop medicines on your own.
Is plasma exchange routinely used to prevent FCS pancreatitis during pregnancy?
No. Therapeutic plasma exchange filters blood to remove excess fat and may be considered case by case in an expert center for extreme or treatment-resistant triglyceride levels, but it has procedural risks and its benefit may be temporary.
Can my children inherit FCS if I have it?
A person with FCS passes one disease-causing gene variant to each child, so each child is expected to be a carrier. A child develops FCS only if the other biological parent also passes down a harmful variant in the same gene; genetic counseling can clarify testing and risk.
What testing should my family consider if I have FCS?
A genetic counselor can use your specific gene findings and family history to decide whether relatives or children should be tested. Early lipid testing may also be appropriate for children who show signs such as milky-looking blood during a blood draw.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Familial chylomicronemia syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How often should I have my fasting triglycerides and HbA1c checked to monitor for long-term pancreatic damage?
  2. 2.What signs of pancreatic insufficiency (like changes in digestion or weight loss) should I be watching for?
  3. 3.If I plan to become pregnant, how soon should we start meeting with a Maternal-Fetal Medicine specialist?
  4. 4.Are there specific pregnancy safety considerations for the targeted lipid therapies I am taking?
  5. 5.Can we set up a genetic counseling session to discuss testing for my children or siblings?
  6. 6.If my partner is also a carrier for an LPL-pathway variant, what does that mean for our future children?

References

References (24)
  1. 1

    Familial chylomicronemia syndrome: Bringing to life dietary recommendations throughout the life span.

    Williams L, Rhodes KS, Karmally W, et al.

    Journal of clinical lipidology 2018; (12(4)):908-919 doi:10.1016/j.jacl.2018.04.010.

    PMID: 29804909
  2. 2

    Familial chylomicronemia syndrome: An expert clinical review from the National Lipid Association.

    Javed F, Hegele RA, Garg A, et al.

    Journal of clinical lipidology 2025; (19(3)):382-403 doi:10.1016/j.jacl.2025.03.013.

    PMID: 40234111
  3. 3

    Severe Familial Chylomicronemia Syndrome With Refractory Hypertriglyceridemia and Multisystem Complications Managed With Chronic Plasmapheresis and Olezarsen: A Case Report.

    Ahmad CM, Kastle RA, Patel H, et al.

    Cureus 2026; (18(3)):e105594 doi:10.7759/cureus.105594.

    PMID: 42017072
  4. 4

    Familial chylomicronemia: New perspectives.

    Blanco Echevarría A, Ariza Corbo MJ, Muñiz-Grijalvo O, Díaz-Díaz JL

    Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis 2024; (36 Suppl 2()):S18-S24 doi:10.1016/j.arteri.2024.10.006.

    PMID: 39672668
  5. 5

    10-Year Comparative Follow-up of Familial versus Multifactorial Chylomicronemia Syndromes.

    Belhassen M, Van Ganse E, Nolin M, et al.

    The Journal of clinical endocrinology and metabolism 2021; (106(3)):e1332-e1342 doi:10.1210/clinem/dgaa838.

    PMID: 33221907
  6. 6

    Volanesorsen in the Treatment of Familial Chylomicronemia Syndrome or Hypertriglyceridaemia: Design, Development and Place in Therapy.

    Esan O, Wierzbicki AS

    Drug design, development and therapy 2020; (14()):2623-2636 doi:10.2147/DDDT.S224771.

    PMID: 32753844
  7. 7

    Non-Alcoholic Fatty Liver in Patients with Chylomicronemia.

    Maltais M, Brisson D, Gaudet D

    Journal of clinical medicine 2021; (10(4)) doi:10.3390/jcm10040669.

    PMID: 33572376
  8. 8

    Recognition and management of persistent chylomicronemia: A Joint Expert Clinical Consensus by the National Lipid Association and the American Society for Preventive Cardiology.

    Saadatagah S, Larouche M, Naderian M, et al.

    Journal of clinical lipidology 2025; (19(4)):723-736 doi:10.1016/j.jacl.2025.03.012.

    PMID: 40360374
  9. 9

    Familial chylomicronaemia syndrome in pregnancy - report of two cases managed with plasma exchange.

    Dos Santos F, Walji S, Cegla J, et al.

    Obstetric medicine 2025; (18(3)):186-189 doi:10.1177/1753495X241283628.

    PMID: 39553182
  10. 10

    Clinical profile, genetic spectrum and therapy evaluation of 19 Chinese pediatric patients with lipoprotein lipase deficiency.

    Xia Y, Zheng W, Du T, et al.

    Journal of clinical lipidology 2023; (17(6)):808-817 doi:10.1016/j.jacl.2023.09.012.

    PMID: 37858495
  11. 11

    Treatment of chylomicronemia.

    Navarro Hermoso A, Valdivielso P

    Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis 2021; (33 Suppl 2()):75-79 doi:10.1016/j.arteri.2021.01.004.

    PMID: 34006359
  12. 12

    Case Report: Conventional therapy versus volanesorsen in two sisters with familial chylomicronemia syndrome.

    Vega J, Torres B, Maiz A, Santos JL

    Frontiers in nutrition 2026; (13()):1749264 doi:10.3389/fnut.2026.1749264.

    PMID: 41737337
  13. 13

    Course of Pregnancies and Occurrence of Acute Pancreatitis in Women With Chylomicronemia.

    Larouche M, Bergeron J, Brisson D, et al.

    The Journal of clinical endocrinology and metabolism 2026; (111(2)):e455-e461 doi:10.1210/clinem/dgaf409.

    PMID: 40663639
  14. 14

    Navigating hypertriglyceridemia in pregnancy: current evidence and clinical strategies.

    Chamerski S, Wartecka-Zielińska K, Pomorski F, et al.

    Frontiers in endocrinology 2026; (17()):1761761 doi:10.3389/fendo.2026.1761761.

    PMID: 42181215
  15. 15

    Management of a pregnant patient with chylomicronemia from a novel mutation in GPIHBP1: a case report.

    Lin MH, Tian XH, Hao XL, et al.

    BMC pregnancy and childbirth 2020; (20(1)):272 doi:10.1186/s12884-020-02965-1.

    PMID: 32375710
  16. 16

    Prophylactic therapeutic plasma exchange in pregnant woman with Familial Chylomicronemia Syndrome - A case report.

    Pećin I, Leskovar D, Šabić M, et al.

    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 2022; (61(3)):103346 doi:10.1016/j.transci.2021.103346.

    PMID: 34924316
  17. 17

    Therapeutic plasma exchange for the management of severe gestational hypertriglyceridaemic pancreatitis due to lipoprotein lipase mutation.

    Kim AS, Hakeem R, Abdullah A, et al.

    Endocrinology, diabetes & metabolism case reports 2020; (2020()).

    PMID: 32168469
  18. 18

    Familial chylomicronemia syndrome: an under-recognized cause of severe hypertriglyceridaemia.

    Baass A, Paquette M, Bernard S, Hegele RA

    Journal of internal medicine 2020; (287(4)):340-348 doi:10.1111/joim.13016.

    PMID: 31840878
  19. 19

    Heterozygosity for pathogenic variants in familial chylomicronemia syndrome genes: from carrier state to complex trait.

    Hegele RA

    Current opinion in lipidology 2026; (37(4)):131-138 doi:10.1097/MOL.0000000000001048.

    PMID: 42308165
  20. 20

    A Novel APOC2 Mutation in a Colombian Patient with Recurrent Hypertriglyceridemic Pancreatitis.

    Pinilla-Monsalve GD, Lores J, Pachajoa H, et al.

    The application of clinical genetics 2020; (13()):63-69 doi:10.2147/TACG.S243148.

    PMID: 32280258
  21. 21

    Heterogeneous nature of severe hypertriglyceridemia in childhood.

    Ariza MJ, Rioja J, Seidel VA, et al.

    Journal of clinical lipidology 2026; (20(3)):629-638 doi:10.1016/j.jacl.2025.12.022.

    PMID: 41688327
  22. 22

    Familial chylomicronemia syndrome: case reports of siblings with deletions of the GPIHBP1 gene.

    Kim KY, Heo YJ, Ko JM, et al.

    BMC endocrine disorders 2024; (24(1)):47 doi:10.1186/s12902-024-01574-9.

    PMID: 38622573
  23. 23

    Can genetic testing help in the management of dyslipidaemias?

    Lazarte J, Hegele RA

    Current opinion in lipidology 2020; (31(4)):187-193 doi:10.1097/MOL.0000000000000690.

    PMID: 32520779
  24. 24

    Pathogenicity assessment of genetic variants identified in patients with severe hypertriglyceridemia: Novel cases of familial chylomicronemia syndrome from the Dyslipidemia Registry of the Spanish Atherosclerosis Society.

    Ariza MJ, Coca-Prieto I, Rioja J, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2025; (27(5)):101365 doi:10.1016/j.gim.2025.101365.

    PMID: 39873189

This page is for informational purposes only and does not constitute medical advice. Your lipid specialist, pregnancy care team, and genetic counselor should guide decisions about monitoring, medications, pregnancy, and family testing.